lancet-header

Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.

Prospective Evaluation of a Rapid Clinical Metagenomics Test for Bacterial Pneumonia

149 Pages Posted: 4 Feb 2021

See all articles by Shengrui Mu

Shengrui Mu

Capital Medical University - China-Japan Friendship Hospital

Long Hu

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Ye Zhang

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Yinmei Liu

Capital Medical University - China-Japan Friendship Hospital

Xiaojing Cui

Capital Medical University - China-Japan Friendship Hospital

Xiaohui Zou

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

Yeming Wang

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

Binghuai Lu

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

Shuilian Zhou

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Xiaoxue Liang

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Chen Liang

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Nick Xiao

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Justin O’Grady

University of East Anglia (UEA) - Norwich Medical School

Shela Li

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Bin Cao

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

CAP-China Network

Independent

More...

Abstract

Background: The diagnosis of bacterial pathogens in lower respiratory tract infections (LRI) using conventional culture methods remains challenging and time-consuming.

Methods: We enrolled 292 consecutively hospitalized patients suspected to have LRI between November 2018 and June 2019 in a single-center, prospective cohort study. Rapid clinical metagenomics test was performed on-site, and the results were compared with those of routine microbiology tests and evaluated for potential clinical benefit.

Results: 171 bronchoalveolar lavage fluid (BAL) and 121 sputum samples were collected from patients with six kinds of LRI. The turn around-time (from sample registration to result) for the rapid metagenomics test was 6.4 ± 1.4 hours, compared to 94.8 ± 34.9 hours for routine culture. Compared with culture and real-time PCR tests, rapid metagenomics achieved 96.6% sensitivity and 88.0% specificity and identified pathogens in 63 out of 161 (39.1%) culture-negative samples. Correlation of anaerobes enrichment with lung abscess was demonstrated as 38 anaerobic species failed in culture but identified by metagenomics sequencing. The hypothetical impact of metagenomics test proposed antibiotic de-escalation in 34 patients compared to 1 using routine culture.

Conclusions: Rapid clinical metagenomics test increased pathogen detection yield  in the diagnosis of LRI. Empirical antimicrobial therapy could be de-escalated if rapid metagenomics test results were hypothetically applied to clinical management.

Funding: The funder of the study had no role in study design, data collection,data analysis, data
interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Declaration of Interest: None to declare

Ethical Approval: The study was carried out in China-Japan Friendship Hospital, Beijing, China. Ethical approval was obtained from the China-Japan Friendship Hospital Ethics Committee(2018-145-k102). All subjects provided written consents.

Keywords: Nanopore sequencing, lower respiratory infections, rapid diagnostics

Suggested Citation

Mu, Shengrui and Hu, Long and Zhang, Ye and Liu, Yinmei and Cui, Xiaojing and Zou, Xiaohui and Wang, Yeming and Lu, Binghuai and Zhou, Shuilian and Liang, Xiaoxue and Liang, Chen and Xiao, Nick and O’Grady, Justin and Li, Shela and Cao, Bin and Network, CAP-China, Prospective Evaluation of a Rapid Clinical Metagenomics Test for Bacterial Pneumonia. Available at SSRN: https://ssrn.com/abstract=3779202 or http://dx.doi.org/10.2139/ssrn.3779202

Shengrui Mu

Capital Medical University - China-Japan Friendship Hospital

China

Long Hu

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Ye Zhang

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Yinmei Liu

Capital Medical University - China-Japan Friendship Hospital

China

Xiaojing Cui

Capital Medical University - China-Japan Friendship Hospital

China

Xiaohui Zou

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

China

Yeming Wang

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

Beijing
China

Binghuai Lu

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine

Beijing
China

Shuilian Zhou

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development ( email )

Xiaoxue Liang

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development ( email )

Chen Liang

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development

Nick Xiao

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development ( email )

Justin O’Grady

University of East Anglia (UEA) - Norwich Medical School ( email )

Norwich
United Kingdom

Shela Li

Simcere Diagnostics Co., Ltd. - State Key Laboratory of Translational Medicine and Innovative Drug Development ( email )

Bin Cao (Contact Author)

China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine ( email )

Beijing
China

CAP-China Network

Independent